How does Semaglutide (GLP-1)'s half-life affect dosing?

Semaglutide (GLP-1) has a plasma half-life of ~7 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at 0.25-2.4 mg weekly (titrated) per dose explains the typical onset timeline for sourcing and quality-control endpoints.

Is Semaglutide (GLP-1) safe during pregnancy or breastfeeding?

Semaglutide (GLP-1), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What should I look for in Semaglutide (GLP-1) sourcing and quality?

Acceptable Semaglutide (GLP-1) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~4114 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the standard dosing protocol for Semaglutide (GLP-1)?

Conventional Semaglutide (GLP-1) dosing is 0.25-2.4 mg weekly (titrated) 1x weekly subq via subq/oral (rybelsus, 7-14 mg daily). For sourcing and quality-control use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of Semaglutide (GLP-1)?

Semaglutide (GLP-1) regulatory status: Approved (Ozempic 2017, Wegovy 2021) in the United States; WADA status not on prohibited list; research level extensive phase iii and post-marketing. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For sourcing and quality-control use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Home/ Compounds/ Semaglutide (GLP-1)

Semaglutide (GLP-1)

Sourcing Guide

Sourcing Semaglutide (GLP-1) from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.

Sourcing / Quality / Procurement Applications

COA ReviewVendor ComparisonStorage ProtocolRegulatory SourcingBAC Water Sourcing

Key Takeaways

Procurement lens: Semaglutide (GLP-1) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching ~4114 Da.
Mechanism: Selective GLP-1 receptor agonist.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

For procurement of Semaglutide (GLP-1), the relevant QC framework covers analytical purity (HPLC), structural identity (mass spec), microbiological safety (endotoxin), and stoichiometric correctness where applicable. Selective GLP-1 receptor agonist. Augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally in the arcuate nucleus to suppress appetite. Fatty acid sidechain and substitutions extend half-life to ~7 days. The subsections below address each QC layer and the vendor-tier landscape.

COA evaluation and red flags

Acceptable Semaglutide (GLP-1) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for Semaglutide (GLP-1) is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of ~4114 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

Vendor tier comparison and price discipline

Three vendor tiers operate in the Semaglutide (GLP-1) market: pharmaceutical-grade compounded prescription (physician-supervised, full COA, ICP-MS where relevant, highest cost), reputable research-chemical vendors (full COA, lot-specific, mid-tier cost), and grey-market unverified sources (template or absent COA, unverifiable supply chain, lowest cost). The price differential between tiers is roughly 3–5x; the quality differential is substantially larger and concentrated in the bottom tier.

Sourcing / Quality / Procurement Applications

Vendor Comparison

Sourcing Semaglutide (GLP-1) for vendor comparison use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Vial Inspection

For users targeting vial inspection, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Cold Chain

Pharmaceutical-grade compounded Semaglutide (GLP-1) is the lowest-risk sourcing path for cold chain use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Shelf Life

Sourcing Semaglutide (GLP-1) for shelf life use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-2.4 mg weekly (titrated)	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-2.4 mg weekly (titrated)	4–6 weeks initial cycle
Sourcing Guide focus	SubQ	0.25-2.4 mg weekly (titrated)	1x weekly SubQ
Maintenance phase	SubQ	1.25-2.4 mg weekly (titrated)	Ongoing with periodic pauses

Dose timing for Semaglutide (GLP-1) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semaglutide (GLP-1) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

Semaglutide (GLP-1) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Semaglutide (GLP-1)'s mechanism in sourcing / quality / procurement protocols.
Semaglutide (GLP-1) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Semaglutide (GLP-1)'s mechanism in sourcing / quality / procurement protocols.
Semaglutide (GLP-1) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Semaglutide (GLP-1)'s mechanism in sourcing / quality / procurement protocols.
Semaglutide (GLP-1) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Semaglutide (GLP-1)'s mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Ozempic 2017, Wegovy 2021) Research: Extensive Phase III and post-marketing

GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated.

Lens-specific safety considerations for sourcing / quality / procurement use of Semaglutide (GLP-1): GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

STEP 1 — Once-weekly semaglutide in adults with overweight or obesity

PMID 33567185

Supporting

STEP 2 — Semaglutide in type 2 diabetes and obesity

PMID 33567186

Semaglutide (GLP-1) vs Related Peptides

Compound	Profile	Onset	Best For
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

What should I check on a Semaglutide (GLP-1) COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching ~4114 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

Pharmaceutical-grade versus research-grade?

Pharmaceutical-grade is GMP-manufactured, COA-backed, prescription-dispensed material with comprehensive quality assurance. Research-grade is laboratory-purpose, COA-backed, not dispensed under prescription. Quality varies substantially between research-grade vendors; pharmaceutical-grade has a tighter quality distribution and a higher price.

Storage protocol?

Lyophilised: −20°C for 18–24 months. Reconstituted with bacteriostatic water: 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Cold-chain shipping is preferred for purchases; insulated packaging without active cooling is acceptable for shorter transit windows.

Reconstitution best practices?

Use sterile bacteriostatic water (0.9% benzyl alcohol). Inject the BAC water down the side of the vial, not directly onto the lyophilised powder. Allow gentle dissolution; do not shake vigorously — swirl the vial. Label the reconstituted vial with concentration and date.

What is the evidence base for Semaglutide (GLP-1)?

Semaglutide (GLP-1)'s evidence base sits at extensive phase iii and post-marketing. The references on this page summarise 3 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What are the procurement red flags for Semaglutide (GLP-1)?

Six markers to evaluate when sourcing Semaglutide (GLP-1): lot-specific COAs available; HPLC purity ≥98% confirmed; mass spec confirming ~4114 Da; endotoxin testing for SubQ-route material; physical address and regulatory disclosure on vendor site; cold-chain shipping options. Multiple missing markers = walk away. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Clinical Protocol

Start a Semaglutide (GLP-1) Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified Semaglutide (GLP-1) and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: ~4114 Da
Sequence length: 31 aa
Half-life: ~7 days
WADA: Not on prohibited list
FDA: Approved (Ozempic 2017, Wegovy 2021)
Research: Extensive Phase III and post-marketing

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semaglutide (GLP-1) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for Semaglutide (GLP-1)

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised